Just last month, Purdue Pharma had agreed to settle their lawsuit with Oklahoma over OxyContin, for at least $270 million, as a result of illegal marketing tactics that had been used to sell the controversial painkiller.
Now, they're facing another lawsuit update by Connecticut, as the AG there prepares plans to file an amended lawsuit against the company and its owners as well.
They've faced accusations of using deceptive marketing and distribution tactics, among other allegations.
It's been suggested that Purdue knowingly misled doctors about their products, when they sought to overstate the benefits and downplay the potential risks of the product.
Because of the controversy and mounting pressure against them over their Oxycontin product, they previously declared that they would drastically cut their US sales staff and stop marketing that product to doctors in the country, but many would say that the damage has already been done.
According to the AG for Connecticut, the expanded lawsuit is going to include directors of the company, shareholders, and officers, who are named as defendants. They will be bringing up more specific details about the alleged misconduct that the company engaged in, particularly with a focus on allegedly highlighting the controversial efforts to boost sales and push addiction.
Purdue and the family behind the company continue to deny the allegations that have been brought up. They've previously attempted to ask the court to toss out suits that have been launched against them over the opioid crisis.
But Connecticut's AG says that the company and the family behind it aren't going to be allowed to "cry poverty” so easily, seeing as it's alleged that they transferred hundreds of millions of dollars fraudulently to members of the family, in an effort to allegedly try and evade liability.
Other states have already filed lawsuits against the company, including Illinois, Oregon, New York, and many more. Purdue executives and directors continue to deny the allegations that have been made and are expected to continue defending themselves against what they say are misleading and cherry-picked attacks.
Pics:
pixabay
